Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-MPZL1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein often referred to as MPZL or Myelin Protein Zero-like 1 (MPZL1) plays a significant role in cellular processes. It is a transmembrane glycoprotein with an approximated molecular mass of about 32.7 kDa. MPZL1 is expressed in various tissues with higher levels found in lung liver kidney and heart. Researchers also identify it under other names including Epithelial V-like Antigen (EVA) or IGSF8 and it typically contributes to cell adhesion and communication.
Biological function summary
MPZL1 supports critical functions like cell proliferation and differentiation through its interactions with other cellular components. It often associates with cytoplasmic signaling proteins suggesting its role in forming larger signaling complexes. MPZL1 engages in downstream signaling pathways when it binds to ligands influencing cellular dynamics and enabling proper tissue development and maintenance. Its interaction with other proteins furthers understanding of its involvement in cellular structural integrity.
Pathways
MPZL1 integrates into important cellular signaling cascades including the MAPK and PI3K-AKT pathways. Within these pathways MPZL1 modulates activity by contacting proteins like GRB2 and PIK3R1 influencing signals that are important for cellular growth and survival. Its activity in these pathways suggests an adaptive role in regulating cellular responses to external stimuli contributing to proper physiological function.
MPZL1 shows significant connection to cancer and fibrosis contexts. Researchers observe alterations in MPZL1 expression levels in certain cancers suggesting potential roles in tumor progression and metastasis. Additionally its link to fibrosis indicates a possible involvement in pathological tissue remodeling. Connections between MPZL1 PDGF receptors and fibrotic processes highlight the importance of understanding MPZL1 in disease mechanisms for potential therapeutic targets.
